{
    "info": {
        "nct_id": "NCT06112613",
        "official_title": "Improving Medication Adherence in Metastatic Breast Cancer Using a Connected Customized Treatment Platform (CONCURxP)",
        "inclusion_criteria": "* NON-PATIENT: Participants must be an oncology healthcare provider (i.e., oncologist, advanced practice provider, or oncology nurse)\n* NON-PATIENT: Participants must have taken care of at least one patient randomized to Arm B (CONCURxP) who had less than 85% adherence rate at 12 months as measured by the WiseBag\n* NON-PATIENT: Participant must speak English\n* NON-PATIENT: Participant must be employed at an National Cancer Institute Community Oncology Research Program (NCORP) site for at least 6 months\n* NON-PATIENT: Participant must be able to provide informed consent to participate in this study\n* PATIENT STEP 0: Patient must be >= 18 years of age\n* PATIENT STEP 0: Patient must be fluent in written and spoken English OR patient must be fluent in written and spoken Spanish\n* PATIENT STEP 0: Patient must present with new or established pathologically proven hormone receptor (HR)+ HER2- metastatic breast cancer at the time of Step 0\n* PATIENT STEP 0: Patient must have initiated any of the CKD4/6 inhibitors (palbociclib or Ibrance, ribociclib or Kisqali, abemaciclib or Verzenio) within 30 days prior to consenting to Step 0 or have received a prescription order with stated intent to initiate within 30 days following Step 0 consent\n\n  * NOTE: Patients who have been treated previously with anticancer treatments other than CDK4/6 inhibitors are eligible\n  * NOTE: CDK4/6 inhibitors must be provided/supplied as a single agent blister pack. If the medication is supplied as capsules in a pill bottle (e.g., Ibrance capsules), patient is not eligible\n  * NOTE: Ribociclib (Kisqali) and abemaciclib (Verzenio) are only available in blister packs. Palbociclib (Ibrance) is the only CDK4/6 inhibitor that might be available in a capsule formulation. However, this is an outdated formulation and is rarely prescribed as a new start. The format of ordered palbociclib can be determined based on the prescription order\n* PATIENT STEP 0: Patients must not have been previously treated with any of the following CDK4/6 inhibitors: Palbociclib or Ibrance, ribociclib or Kisqali, and abemaciclib or Verzenio\n* PATIENT STEP 0: Patients must not already be enrolled in a therapeutic clinical trial that monitors CDK4/6 inhibitors\n* PATIENT STEP 0: Patient must confirm that they intend to receive their care or monitoring at an NCORP site\n* PATIENT STEP 0: Patient must have a personal mobile phone in which they are able and willing to send and receive text messages\n\n  * NOTE: The restriction to those with mobile phone access with text messaging is based on the primary intention of the study which involves the use of text messaging to improve adherence\n* PATIENT STEP 0: Patient must have an email address\n\n  * NOTE: The restriction to those with an email address is based on the primary intention of the study which involves patients responding to questions regarding their reasons for non-adherence after every missed dose to improve adherence\n* PATIENT STEP 0: Patient must have the ability to understand and the willingness to sign a written informed consent document\n\n  * NOTE: Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available are not eligible\n* PATIENT STEP 0: Patient must not have an Eastern Cooperative Oncology Group (ECOG) performance status >= 3 OR patient must not be deemed medically unable to participate in the study by the study investigators or an oncology clinician (i.e., referral to hospice)\n* PATIENT STEP 0: Patient must not be enrolled in other trials offering financial assistance\n\n  * NOTE: Gift cards for survey completion, parking passes, or free medication provided as part of therapeutic trials are not considered financial assistance\n* PATIENT STEP 1: Patient must meet all the eligibility criteria for Step 0\n* PATIENT STEP 1: Patient must have signed a written informed consent form\n* PATIENT STEP 1: Patient must have completed baseline survey within 30 days of the date of Step 0 Registration\n* PATIENT STEP 1: Patients must have initiated their CDK 4/6 inhibitors within 30 days of the date of Step 0 registration\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* PATIENT STEP 0: Patients must not have been previously treated with any of the following CDK4/6 inhibitors: Palbociclib or Ibrance, ribociclib or Kisqali, and abemaciclib or Verzenio",
            "criterions": [
                {
                    "exact_snippets": "must not have been previously treated with any of the following CDK4/6 inhibitors: Palbociclib or Ibrance, ribociclib or Kisqali, and abemaciclib or Verzenio",
                    "criterion": "prior treatment with CDK4/6 inhibitors (Palbociclib/Ibrance, ribociclib/Kisqali, abemaciclib/Verzenio)",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENT STEP 0: Patient must not be enrolled in other trials offering financial assistance",
            "criterions": [
                {
                    "exact_snippets": "Patient must not be enrolled in other trials offering financial assistance",
                    "criterion": "enrollment in other trials offering financial assistance",
                    "requirements": [
                        {
                            "requirement_type": "enrollment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: The restriction to those with an email address is based on the primary intention of the study which involves patients responding to questions regarding their reasons for non-adherence after every missed dose to improve adherence",
            "criterions": [
                {
                    "exact_snippets": "restriction to those with an email address",
                    "criterion": "email address",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NON-PATIENT: Participant must be able to provide informed consent to participate in this study",
            "criterions": [
                {
                    "exact_snippets": "Participant must be able to provide informed consent to participate in this study",
                    "criterion": "ability to provide informed consent",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENT STEP 0: Patient must confirm that they intend to receive their care or monitoring at an NCORP site",
            "criterions": [
                {
                    "exact_snippets": "Patient must confirm that they intend to receive their care or monitoring at an NCORP site",
                    "criterion": "intention to receive care or monitoring at an NCORP site",
                    "requirements": [
                        {
                            "requirement_type": "intention/confirmation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENT STEP 0: Patient must have initiated any of the CKD4/6 inhibitors (palbociclib or Ibrance, ribociclib or Kisqali, abemaciclib or Verzenio) within 30 days prior to consenting to Step 0 or have received a prescription order with stated intent to initiate within 30 days following Step 0 consent",
            "criterions": [
                {
                    "exact_snippets": "Patient must have initiated any of the CKD4/6 inhibitors (palbociclib or Ibrance, ribociclib or Kisqali, abemaciclib or Verzenio) within 30 days prior to consenting to Step 0",
                    "criterion": "CKD4/6 inhibitor initiation",
                    "requirements": [
                        {
                            "requirement_type": "initiation_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to Step 0 consent"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "or have received a prescription order with stated intent to initiate within 30 days following Step 0 consent",
                    "criterion": "CKD4/6 inhibitor prescription order with intent to initiate",
                    "requirements": [
                        {
                            "requirement_type": "initiation_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days following Step 0 consent"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENT STEP 1: Patient must have completed baseline survey within 30 days of the date of Step 0 Registration",
            "criterions": [
                {
                    "exact_snippets": "Patient must have completed baseline survey",
                    "criterion": "baseline survey",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "within 30 days of the date of Step 0 Registration",
                    "criterion": "baseline survey completion date",
                    "requirements": [
                        {
                            "requirement_type": "time from Step 0 Registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENT STEP 0: Patient must not have an Eastern Cooperative Oncology Group (ECOG) performance status >= 3 OR patient must not be deemed medically unable to participate in the study by the study investigators or an oncology clinician (i.e., referral to hospice)",
            "criterions": [
                {
                    "exact_snippets": "Patient must not have an Eastern Cooperative Oncology Group (ECOG) performance status >= 3",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patient must not be deemed medically unable to participate in the study by the study investigators or an oncology clinician (i.e., referral to hospice)",
                    "criterion": "medical ability to participate in the study",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: CDK4/6 inhibitors must be provided/supplied as a single agent blister pack. If the medication is supplied as capsules in a pill bottle (e.g., Ibrance capsules), patient is not eligible",
            "criterions": [
                {
                    "exact_snippets": "CDK4/6 inhibitors must be provided/supplied as a single agent blister pack",
                    "criterion": "CDK4/6 inhibitor medication packaging",
                    "requirements": [
                        {
                            "requirement_type": "packaging type",
                            "expected_value": "single agent blister pack"
                        }
                    ]
                },
                {
                    "exact_snippets": "If the medication is supplied as capsules in a pill bottle (e.g., Ibrance capsules), patient is not eligible",
                    "criterion": "CDK4/6 inhibitor medication packaging",
                    "requirements": [
                        {
                            "requirement_type": "packaging type",
                            "expected_value": {
                                "operator": "!=",
                                "value": 1,
                                "unit": "pill bottle with capsules"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENT STEP 0: Patients must not already be enrolled in a therapeutic clinical trial that monitors CDK4/6 inhibitors",
            "criterions": [
                {
                    "exact_snippets": "Patients must not already be enrolled in a therapeutic clinical trial that monitors CDK4/6 inhibitors",
                    "criterion": "enrollment in a therapeutic clinical trial that monitors CDK4/6 inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NON-PATIENT: Participants must have taken care of at least one patient randomized to Arm B (CONCURxP) who had less than 85% adherence rate at 12 months as measured by the WiseBag",
            "criterions": [
                {
                    "exact_snippets": "Participants must have taken care of at least one patient randomized to Arm B (CONCURxP)",
                    "criterion": "care of patient in Arm B (CONCURxP)",
                    "requirements": [
                        {
                            "requirement_type": "number of patients cared for",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "patients"
                            }
                        },
                        {
                            "requirement_type": "patient assignment",
                            "expected_value": "randomized to Arm B (CONCURxP)"
                        }
                    ]
                },
                {
                    "exact_snippets": "who had less than 85% adherence rate at 12 months as measured by the WiseBag",
                    "criterion": "patient adherence rate at 12 months (WiseBag)",
                    "requirements": [
                        {
                            "requirement_type": "adherence rate",
                            "expected_value": {
                                "operator": "<",
                                "value": 85,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "12 months"
                        },
                        {
                            "requirement_type": "measurement method",
                            "expected_value": "WiseBag"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: The restriction to those with mobile phone access with text messaging is based on the primary intention of the study which involves the use of text messaging to improve adherence",
            "criterions": [
                {
                    "exact_snippets": "restriction to those with mobile phone access with text messaging",
                    "criterion": "mobile phone access with text messaging",
                    "requirements": [
                        {
                            "requirement_type": "access",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NON-PATIENT: Participant must be employed at an National Cancer Institute Community Oncology Research Program (NCORP) site for at least 6 months",
            "criterions": [
                {
                    "exact_snippets": "Participant must be employed at an National Cancer Institute Community Oncology Research Program (NCORP) site",
                    "criterion": "employment at NCORP site",
                    "requirements": [
                        {
                            "requirement_type": "employment_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "employed at an National Cancer Institute Community Oncology Research Program (NCORP) site for at least 6 months",
                    "criterion": "duration of employment at NCORP site",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: Patients who have been treated previously with anticancer treatments other than CDK4/6 inhibitors are eligible",
            "criterions": [
                {
                    "exact_snippets": "Patients who have been treated previously with anticancer treatments other than CDK4/6 inhibitors are eligible",
                    "criterion": "prior anticancer treatment",
                    "requirements": [
                        {
                            "requirement_type": "type of prior treatment",
                            "expected_value": "anticancer treatments other than CDK4/6 inhibitors"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: Ribociclib (Kisqali) and abemaciclib (Verzenio) are only available in blister packs. Palbociclib (Ibrance) is the only CDK4/6 inhibitor that might be available in a capsule formulation. However, this is an outdated formulation and is rarely prescribed as a new start. The format of ordered palbociclib can be determined based on the prescription order",
            "criterions": [
                {
                    "exact_snippets": "Ribociclib (Kisqali) and abemaciclib (Verzenio) are only available in blister packs",
                    "criterion": "ribociclib and abemaciclib formulation",
                    "requirements": [
                        {
                            "requirement_type": "formulation",
                            "expected_value": "blister pack"
                        }
                    ]
                },
                {
                    "exact_snippets": "Palbociclib (Ibrance) is the only CDK4/6 inhibitor that might be available in a capsule formulation",
                    "criterion": "palbociclib formulation",
                    "requirements": [
                        {
                            "requirement_type": "formulation",
                            "expected_value": [
                                "capsule",
                                "blister pack"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "this is an outdated formulation and is rarely prescribed as a new start",
                    "criterion": "palbociclib capsule formulation prescription status",
                    "requirements": [
                        {
                            "requirement_type": "prescription status",
                            "expected_value": "rarely prescribed as new start"
                        }
                    ]
                },
                {
                    "exact_snippets": "The format of ordered palbociclib can be determined based on the prescription order",
                    "criterion": "palbociclib formulation determination",
                    "requirements": [
                        {
                            "requirement_type": "determination method",
                            "expected_value": "prescription order"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENT STEP 1: Patient must meet all the eligibility criteria for Step 0",
            "criterions": [
                {
                    "exact_snippets": "Patient must meet all the eligibility criteria for Step 0",
                    "criterion": "Step 0 eligibility criteria",
                    "requirements": [
                        {
                            "requirement_type": "fulfillment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NON-PATIENT: Participants must be an oncology healthcare provider (i.e., oncologist, advanced practice provider, or oncology nurse)",
            "criterions": [
                {
                    "exact_snippets": "Participants must be an oncology healthcare provider (i.e., oncologist, advanced practice provider, or oncology nurse)",
                    "criterion": "participant occupation",
                    "requirements": [
                        {
                            "requirement_type": "occupation type",
                            "expected_value": [
                                "oncologist",
                                "advanced practice provider",
                                "oncology nurse"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENT STEP 1: Patients must have initiated their CDK 4/6 inhibitors within 30 days of the date of Step 0 registration",
            "criterions": [
                {
                    "exact_snippets": "Patients must have initiated their CDK 4/6 inhibitors within 30 days of the date of Step 0 registration",
                    "criterion": "CDK 4/6 inhibitor initiation",
                    "requirements": [
                        {
                            "requirement_type": "time from Step 0 registration to CDK 4/6 inhibitor initiation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENT STEP 0: Patient must be >= 18 years of age",
            "criterions": [
                {
                    "exact_snippets": "Patient must be >= 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENT STEP 0: Patient must present with new or established pathologically proven hormone receptor (HR)+ HER2- metastatic breast cancer at the time of Step 0",
            "criterions": [
                {
                    "exact_snippets": "pathologically proven hormone receptor (HR)+ HER2- metastatic breast cancer",
                    "criterion": "breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "pathological confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "hormone receptor status",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "HER2 status",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "metastatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at the time of Step 0",
                    "criterion": "timing of diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "at the time of Step 0"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NON-PATIENT: Participant must speak English",
            "criterions": [
                {
                    "exact_snippets": "Participant must speak English",
                    "criterion": "language proficiency",
                    "requirements": [
                        {
                            "requirement_type": "language",
                            "expected_value": "English"
                        },
                        {
                            "requirement_type": "proficiency",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENT STEP 0: Patient must have the ability to understand and the willingness to sign a written informed consent document",
            "criterions": [
                {
                    "exact_snippets": "ability to understand",
                    "criterion": "cognitive ability",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to sign a written informed consent document",
                    "criterion": "willingness to sign informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENT STEP 0: Patient must be fluent in written and spoken English OR patient must be fluent in written and spoken Spanish",
            "criterions": [
                {
                    "exact_snippets": "Patient must be fluent in written and spoken English",
                    "criterion": "English language fluency",
                    "requirements": [
                        {
                            "requirement_type": "fluency (written and spoken)",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patient must be fluent in written and spoken Spanish",
                    "criterion": "Spanish language fluency",
                    "requirements": [
                        {
                            "requirement_type": "fluency (written and spoken)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENT STEP 0: Patient must have a personal mobile phone in which they are able and willing to send and receive text messages",
            "criterions": [
                {
                    "exact_snippets": "Patient must have a personal mobile phone",
                    "criterion": "personal mobile phone",
                    "requirements": [
                        {
                            "requirement_type": "possession",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "able ... to send and receive text messages",
                    "criterion": "ability to send and receive text messages",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing to send and receive text messages",
                    "criterion": "willingness to send and receive text messages",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENT STEP 1: Patient must have signed a written informed consent form",
            "criterions": [
                {
                    "exact_snippets": "Patient must have signed a written informed consent form",
                    "criterion": "informed consent form",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "form type",
                            "expected_value": "written"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PATIENT STEP 0: Patient must have an email address",
            "criterions": [
                {
                    "exact_snippets": "Patient must have an email address",
                    "criterion": "email address",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available are not eligible",
            "criterions": [
                {
                    "exact_snippets": "Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available are not eligible",
                    "criterion": "impaired decision-making capacity with available LAR or caregiver/family member",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: Gift cards for survey completion, parking passes, or free medication provided as part of therapeutic trials are not considered financial assistance",
            "criterions": [
                {
                    "exact_snippets": "Gift cards for survey completion, parking passes, or free medication provided as part of therapeutic trials are not considered financial assistance",
                    "criterion": "financial assistance",
                    "requirements": [
                        {
                            "requirement_type": "definition",
                            "expected_value": "Gift cards for survey completion, parking passes, or free medication provided as part of therapeutic trials are not considered financial assistance"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}